Anaptysbio, Inc
- Last sale
- Nov 12, 2026 · -2.25%
- Market cap
- $1.42B
- 29.73M shares
- Filings
- 728
Q1 2027+157.0% FY25 yoy
Q1 2027N/M FY25 yoy
Q1 2027N/M FY25 yoy
Q1 2026derivedN/M FY25 yoy
Q1 2027N/M FY25 yoy
Q1 2027−43.8% FY26 yoy
- $1.42B
- —
- 6.1×
- 68.2×
- 1.38%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $234,603,000 | reported | |
| FY 2024 | 2024-12-31 | $91,280,000 | reported | |
| FY 2023 | 2023-12-31 | $17,157,000 | reported | |
| FY 2022 | 2022-12-31 | $10,287,000 | reported | |
| FY 2021 | 2021-12-31 | $63,175,000 | reported | |
| FY 2020 | 2020-12-31 | $75,000,000 | reported | |
| FY 2019 | 2019-12-31 | $8,000,000 | reported | |
| FY 2018 | 2018-12-31 | $5,000,000 | reported | |
| FY 2017 | 2017-12-31 | $10,000,000 | reported | |
| FY 2016 | 2016-12-31 | $16,684,000 | reported | |
| FY 2015 | 2015-12-31 | $17,571,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $68.63M | $68.63M | — | 29.10M sh | −5.1% | 350.0% |
| FY2024 | — | $456.00K | $456.00K | — | 30.67M sh | +14.6% | — |
| FY2023 | — | $50.00M | $50.00M | — | 26.76M sh | −4.2% | — |
| FY2022 | — | $0.00 | $0.00 | — | 27.93M sh | +0.9% | — |
| FY2021 | — | $0.00 | $0.00 | — | 27.67M sh | +1.1% | — |
Segments
Segments
LineFY2025ShareChange
Royalty Management$234.60M100%+157.0%
Biopharma$0.00——
Reportable Segment———
Total$234.60M
Pharmaceutical preparations
Anaptysbio, Inc is the 80th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
SDGRSchrodinger, Inc.$255.9M23.3%40.4%$2.3BRCUSArcus Biosciences, Inc.$247.0M4.3%142.9%$2.6BKROSKeros Therapeutics, Inc.$244.1M6,775.0%35.7%$197.2MAKBAAkebia Therapeutics, Inc.$236.2M47.5%2.3%$138.5M
ANABAnaptysbio, Inc (this company)$234.6M157.0%5.6%$1.4B
PBYIPuma Biotechnology, Inc.$228.4M0.9%13.6%$418.0MIDYAIDEAYA Biosciences, Inc.$218.7M3,024.4%52.0%$3.0BVNDAVanda Pharmaceuticals Inc.$216.1M8.7%102.0%$238.9MAMRNAmarin Corp Plcuk$213.6M6.5%18.2%$4.9BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Anaptysbio, Inc · CIK 1370053 · Engraved from SEC EDGAR